Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04492254Phase 3Terminated

Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients

Role: lead

NCT02444221Completed

Rivaroxaban Evaluation in Real Life Settings

Role: lead

NCT02155491Completed

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

Role: lead

NCT01090362Completed

Global Anticoagulant Registry in the Field

Role: lead

NCT00718354Phase 3Completed

Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT

Role: lead

All 5 trials loaded